Fairvalue-Calculator Fairvalue-Calculator
EN DE

Chunghwa Chemical Synthesis & Biotech Co (1762) Fair Value & Analysis

Healthcare · TW · Market cap 2.7B TWD

Price38.30 TWD
Fair Value26.89 TWD
Upside-29.8%
Quality95/100
Evidence: Medium Range 20.07 TWD – 40.14 TWD

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Chunghwa Chemical Synthesis & Biotech Co (1762) currently trades at 38.30 TWD, while our model-based Fair Value estimate is 26.89 TWD — implying the stock looks roughly 29.8% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

About the company

Chunghwa Chemical Synthesis & Biotech Co., Ltd. engages in the research, development, manufacturing, and sale of active pharmaceutical ingredients in Taiwan, the United States, India, Greece, Croatia, Japan, and internationally. The company offers antifungal, immunosuppressant, oncology, cardiovascular, peptide drug, immunomodulating agents, statin, muscle relaxant, ACE inhibitor with complete DMF or COS, and other API products. It also provides specialty API immunosuppressants, including mycophenolate mofetil, rapamycin, and tacrolimus; derivative of rapamycin, such as everolimus, temsirolimus, zotarolimus, and biolimus; and echinocandin comprising caspofungin, micafungin, and anidulafungin. In addition, the company is also involved in contract manufacturing and research services. It exports its products. The company was formerly known as China Chemical Synthesis Industry Co., Ltd. and changed its name to Chunghwa Chemical Synthesis & Biotech Co., Ltd. in January 2003. Chunghwa Che…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is Chunghwa Chemical Synthesis & Biotech Co (1762) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 26.89 TWD versus a price of 38.30 TWD — about −30% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 1762?
Our 21-model fair value for Chunghwa Chemical Synthesis & Biotech Co is 26.89 TWD (as of Jun 24, 2026), built from audited fundamentals. The current price is 38.30 TWD.
What is the quality score of 1762?
Chunghwa Chemical Synthesis & Biotech Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.